BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2020;41:4415-22. [PMID: 33211823 DOI: 10.1093/eurheartj/ehaa793] [Cited by in Crossref: 15] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Press 2022;31:210-24. [PMID: 36029011 DOI: 10.1080/08037051.2022.2110858] [Reference Citation Analysis]
2 Yan HJ, Zheng XY, Huang H, Xu L, Tang HT, Wang JJ, Li CH, Zhang SX, Fu SY, Wen HY, Tian D. Double-lung versus heart-lung transplantation for end-stage cardiopulmonary disease: a systematic review and meta-analysis. Surg Today 2022. [PMID: 36068414 DOI: 10.1007/s00595-022-02579-4] [Reference Citation Analysis]
3 Tustumi F. Evaluating the Non-conventional Achalasia Treatment Modalities. Front Med 2022;9:941464. [DOI: 10.3389/fmed.2022.941464] [Reference Citation Analysis]
4 Alfonso F, de la Torre Hernández JM, Ibáñez B, Sabaté M, Pan M, Gulati R, Saw J, Angiolillo DJ, Adlam D, Sánchez-madrid F. Diseño y justificación del estudio clínico aleatorizado BA-SCAD (bloqueadores beta y agentes antiplaquetarios en pacientes con disección arterial coronaria espontánea). Revista Española de Cardiología 2022;75:515-22. [DOI: 10.1016/j.recesp.2021.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Arcoraci V, Squadrito F, Rottura M, Barbieri MA, Pallio G, Irrera N, Nobili A, Natoli G, Argano C, Squadrito G, Corrao S. Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register. Front Cardiovasc Med 2022;9:876693. [DOI: 10.3389/fcvm.2022.876693] [Reference Citation Analysis]
6 Takeuchi S, Kohno T, Goda A, Shiraishi Y, Kawana M, Saji M, Nagatomo Y, Nishihata Y, Takei M, Nakano S, Soejima K, Kohsaka S, Yoshikawa T; West Tokyo Heart Failure Registry Investigators. Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Fail 2022. [PMID: 35561100 DOI: 10.1002/ehf2.13954] [Reference Citation Analysis]
7 Su VY, Ko SW, Chang YL, Chou YC, Lee HC, Yang KY, Chou KT, Hsu CC. Cardiovascular Medication Use and Risk of Acute Exacerbation in Patients With Asthma-COPD Overlap (CVACO Study). Allergy Asthma Immunol Res 2022;14:314-27. [PMID: 35557496 DOI: 10.4168/aair.2022.14.3.314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension 2022;79:1153-66. [PMID: 35378981 DOI: 10.1161/HYPERTENSIONAHA.122.19020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lin J, Xue Y, Su W, Zhang Z, Wei Q, Huang T. Identification of Dysregulated Mechanisms and Candidate Gene Markers in Chronic Obstructive Pulmonary Disease. COPD 2022;Volume 17:475-87. [DOI: 10.2147/copd.s349694] [Reference Citation Analysis]
10 Ruzieh M, Baugh AD, Al Jebbawi L, Edwards ES, Jia KQ, Dransfield MT, Foy AJ. Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review: A systematic review of βB in COPD. Trends Cardiovasc Med 2021:S1050-1738(21)00139-0. [PMID: 34856338 DOI: 10.1016/j.tcm.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Verdecchia P, Cavallini C, Coiro S, Riccini C, Angeli F. Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease. Eur Heart J Suppl 2021;23:E172-6. [PMID: 34650380 DOI: 10.1093/eurheartj/suab116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Santus P, Franceschi E, Pini S, Frassanito F, Amati F, Danzo F, Gatti M, Radovanovic D. Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation. Pharmacol Res 2021;173:105915. [PMID: 34571145 DOI: 10.1016/j.phrs.2021.105915] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Alfonso F, de la Torre Hernández JM, Ibáñez B, Sabaté M, Pan M, Gulati R, Saw J, Angiolillo DJ, Adlam D, Sánchez-Madrid F. Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial. Rev Esp Cardiol (Engl Ed) 2021:S1885-5857(21)00248-6. [PMID: 34561195 DOI: 10.1016/j.rec.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Crea F. The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors. Eur Heart J 2021;42:3209-13. [PMID: 34492687 DOI: 10.1093/eurheartj/ehab577] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Damkjær M, Suppli Ulrik C, Godtfredsen N, Håkansson KEJ. Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality - The STATUETTE Cohort Study. Int J Chron Obstruct Pulmon Dis 2021;16:2397-406. [PMID: 34465987 DOI: 10.2147/COPD.S315151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Crea F. New therapeutic targets in lipid lowering: high-sugar feeding in infants, lipoprotein(a), and lipoprotein lipase. Eur Heart J 2021;42:1119-22. [PMID: 33744964 DOI: 10.1093/eurheartj/ehab132] [Reference Citation Analysis]
17 Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Increase use of β-blockers in patients with chronic obstructive pulmonary and cardiovascular disease. Eur Heart J 2021;42:1181. [PMID: 33517398 DOI: 10.1093/eurheartj/ehab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tang H, Yang ZY, Tang JL. β-Blocker and survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease. Eur Heart J 2021;42:1180. [PMID: 33495780 DOI: 10.1093/eurheartj/ehab004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hatefi A, Zare Shahneh A, Ansari Pirsaraie Z, Alizadeh AM, Atashnak MP, Masoudi R, Pio F. The stimulation and inhibition of beta-2 adrenergic receptor on the inflammatory responses of ovary and immune system in the aged laying hens. BMC Vet Res 2021;17:195. [PMID: 34022889 DOI: 10.1186/s12917-021-02892-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Yang YL, Xiang ZJ, Xiang RL. Increasing the prescription rate of β-blockers is beneficial for patients with chronic obstructive pulmonary and cardiovascular disease. Eur Heart J 2021:ehab239. [PMID: 33948636 DOI: 10.1093/eurheartj/ehab239] [Reference Citation Analysis]
21 Gulea C, Quint JK, Zakeri R. Clinical and methodological considerations when interpreting meta-analyses of beta-blocker use in patients with chronic obstructive pulmonary disease. Eur Heart J 2021:ehab217. [PMID: 33948644 DOI: 10.1093/eurheartj/ehab217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 MacDonald MI, Bardin PG. Contemporary Concise Review 2020: Chronic obstructive pulmonary disease. Respirology 2021;26:493-500. [PMID: 33749929 DOI: 10.1111/resp.14037] [Reference Citation Analysis]
23 Wang R, Tomaniak M, Takahashi K, Gao C, Kawashima H, Hara H, Ono M, van Klaveren D, van Geuns RJ, Morice MC, Davierwala PM, Mack MJ, Witkowski A, Curzen N, Berti S, Burzotta F, James S, Kappetein AP, Head SJ, Thuijs DJFM, Mohr FW, Holmes DR, Tao L, Onuma Y, Serruys PW. Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clin Res Cardiol 2021;110:1083-95. [PMID: 33710385 DOI: 10.1007/s00392-021-01833-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res 2021;22:64. [PMID: 33622362 DOI: 10.1186/s12931-021-01661-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Saifi ES, Giorgi-Pierfranceschi M, Salvetti M, Maninetti L, Cavalli I, Muiesan ML. Factors associated with survival in older patients affected by COVID-19: A retrospective cohort study. Arch Gerontol Geriatr 2021;94:104349. [PMID: 33508512 DOI: 10.1016/j.archger.2021.104349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Crea F. A fresh look at ischaemic heart disease: from artificial intelligence to reappraisal of old drugs. Eur Heart J 2020;41:4367-70. [PMID: 33349864 DOI: 10.1093/eurheartj/ehaa964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ferrari R, Pavasini R, Campo G. Beta-blockers and COPD: how can harmony be restored in a marriage in crisis? Eur Heart J 2020;41:4423-4. [PMID: 33316038 DOI: 10.1093/eurheartj/ehaa873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]